Abstract
Purpose. Receptors for vitamin folic acid are frequently overexpressed on epithelial cancer cells, especially ovarian cancer cells. In this study, we examined whether this expression might be exploited to specifically deliver antisense oligodeoxynucleotides (ODN) to tumor cells.
Methods. A conjugate was prepared by directly coupling folic acid to the 3′ terminus of an anti-c-fos ODN and its cellular uptake and tumor inhibitory effect were evaluated using FD2008 cells that overexpress folate receptors.
Results. When a phosphorothioate (PS)/phosphodiester (PO) chimeric ODN was conjugated with folic acid, its uptake by FD2008 cells was increased by about 8-fold (P < 0.01). In contrast, conjugation of folate to the ODN did not increase its uptake by CHO cells that lack the expression of FBP (P > 0.05). Furthermore, the increase in the uptake of conjugated ODN by FD2008 cells could be blocked by adding an excess amount of folic acid. The PS/PO antisense ODN had some inhibitory effect on the growth of FD2008 cells. However, its activity was significantly increased following conjugation with folic acid (P < 0.01). ODN of scrambled sequences with and without conjugation with folic acid failed to inhibit the growth of FD2008 cells. Finally, the antisense effect of the conjugated ODN on FD2008 cells was inhibited by an excess amount of free folic acid, suggesting that the sequence-dependent effect of folate-antisense ODN conjugate was mediated by folate binding protein.
Conclusions. Direct derivatization of ODN with folate significantly improves their targeting efficiency to tumor cells in vitro. The folate-conjugated ODN, due to their small size and possibly efficient extravasation at tumor site, has the potential for treating solid tumors that overexpress folate receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
J. S. Cohen. Antisense oligonucleotides as antiviral agents. Antiviral Res. 16:121-133 (1991).
S. T. Crooke. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:329-376 (1992).
C. A. Stein and Y.C. Cheng. Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science 261:1004-1011 (1993).
L. Neckers, L. Whitesell, A. Rosolen, and D. A. Geselowitz. Antisense inhibition of oncogene expression. Crit. Rev. Oncogen. 3:175-231 (1992).
C. Cazenave, P. Frank, and W. Busen. Characterization of ribonuclease H activities present in two cell-free protein synthesizing systems, the wheat germ extract and the rabbit reticulocyte lysate. Biochimie 75:113-122 (1993).
L. A. Yakubov, E. A. Deeva, V. F. Zarytova, E. M. Ivanova, A. S. Ryte, L. V. Yurchenko, and V. V. Vlassov. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86:6454-6458 (1989).
S. Akhtar, S. Basu, E. Wickstrom, and R. L. Juliano. Inetractions of antisense DNA oligonucleotide analogs with phopholipid membranes (liposomes). Nucleic Acids Res. 19:5551-5559 (1991).
S. L. Loke, C. A. Stein, X. H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J. S. Cohen, and L. M. Neckers. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86:3474-3478 (1989).
S. Wang, R. J. Lee, G. Cauchon, D. G. Gorenstein, and P. S. Low. Delivery of antisense oligodeoxyribonucleotides against human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995).
C. F. Bennett, M. Y. Chaing, H. Chan, J. E. E. Shoemaker, and C. K. Mirabelli. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033 (1992).
F. Cumin, F. Asselbergs, M. Lartigot, and E. Felder. Modulation of human protein gene expression by antisense oligonucleotides in transfected CHO cells. Eur. J. Biochem. 212:347-354 (1993).
G. Y. Wu and C. H. Wu. Specific inhibition of hepatitis B viral gene expression by targeted antisense oligonucleotides. J. Biol. Chem. 267:12436-12439 (1992).
G. Citro, C. Szczylik, G. Zupi, and B. Calabretta. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer 69:463-467 (1994).
A. L. Klibanov and L. Huang. Long-circulating liposomes: development and perspectives. J. Liposome Res. 2:321-334 (1992).
D. C. Litzinger, J. M. Brown, I. Wala, S. A. Kaufman, G. Y. Van, C. L. Farrell, and D. Collins. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1281:139-149 (1996).
R. Plourde and G. Y. Wu. Targeted therapy for viral hepatitis. Adv. Drug Delivery Rev. 17:311-315 (1995).
S. Li, X. Y. Zhang, S. Y. Zhang, X. T. Chen, L. J. Chen, Y. H. Shu, J. L. Zhang, and D. M. Fan. Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity. Bioconjugate Chem. 1:245-250 (1990).
K. J. Scanlon, L. Jiao, T. Funato, W. Wang, J. J. Rossi, and M. Kashani-Sabet. Ribozyme-mediated clevage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA 88:10591-10595 (1991).
M. A. Piatyszek, A. Jarmolowski, and J. Augustyniak. IodoGenmediated radioiodination of nucleic acids. Anal. Biochem. 172:356-359 (1988).
M. B. Hansen, S. E. Nielson, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killing. J. Immunol. Methods 119:203-210 (1989).
M. Nesterova and Y. S. Chochung. A single-injection protein-kinase A-directed antisense treatment to inhibit tumor growth. Nature Med. 1:528-533 (1995).
B. A. Kamen, M. T. Wang, A. J. Streckfuss, X. Peryea, and R. G. W. Anderson. Delivery of folates to the cytoplasm of MA 104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263:13602-13609 (1988).
M. A. Kane, P. C. Elwood, R. M. Portillo, A. C. Antony, and J. F. Kolhouse. The interrelationship of the soluble and membrane-associated folate-binding proteins in human KB cells. J. Biol. Chem. 261:15625-15631 (1986).
I. G. Campbell, T. A. Jones, W. D. Foulkes, and J. Trowsdale. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:5329-5338 (1991).
C. P. Leamon and P. S. Low. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267:24966-24971 (1992).
R. J. Lee and P. S. Low. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233:134-144 (1995).
M. E. Greenberg and B. B. Ziff. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 311:433-438 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, S., Deshmukh, H.M. & Huang, L. Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells. Pharm Res 15, 1540–1545 (1998). https://doi.org/10.1023/A:1011946915209
Issue Date:
DOI: https://doi.org/10.1023/A:1011946915209